


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:05:10Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406407" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406407</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>bmcneph</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Nephrol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Nephrol</journal-id><journal-id journal-id-type="pmc-domain-id">47</journal-id><journal-id journal-id-type="pmc-domain">bmcneph</journal-id><journal-title-group><journal-title>BMC Nephrology</journal-title></journal-title-group><issn pub-type="epub">1471-2369</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406407</article-id><article-id pub-id-type="pmcid-ver">PMC12406407.1</article-id><article-id pub-id-type="pmcaid">12406407</article-id><article-id pub-id-type="pmcaiid">12406407</article-id><article-id pub-id-type="pmid">40898097</article-id><article-id pub-id-type="doi">10.1186/s12882-025-04445-0</article-id><article-id pub-id-type="publisher-id">4445</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Development and validation of a nomogram for predicting hyperphosphatemia in non-dialysis patients with chronic kidney disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="X">Xianhui</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zheng</surname><given-names initials="C">Caiyun</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Su</surname><given-names initials="Q">Qitong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lu</surname><given-names initials="D">Dongli</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="S">Shiqin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jiang</surname><given-names initials="Z">Zhenghua</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wu</surname><given-names initials="Z">Zhaochun</given-names></name><address><email>53018640@qq.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/050s6ns64</institution-id><institution-id institution-id-type="GRID">grid.256112.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1797 9307</institution-id><institution>Nanping First Hospital Affiliated to Fujian Medical University, </institution></institution-wrap>Nanping, Fujian China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/050s6ns64</institution-id><institution-id institution-id-type="GRID">grid.256112.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1797 9307</institution-id><institution>Fuqing City Hospital Affiliated to Fujian Medical University, </institution></institution-wrap>Nanping, Fujian China </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>26</volume><issue-id pub-id-type="pmc-issue-id">478197</issue-id><elocation-id>512</elocation-id><history><date date-type="received"><day>27</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>1</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="12882_2025_Article_4445.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Elevated serum phosphate levels are strongly associated with an increased risk of all-cause mortality in patients with chronic kidney disease (CKD). The aim of this study was to identify independent risk factors for hyperphosphatemia in patients with non-dialysis CKD and use the findings to develop and validate a predictive model for assessing hyperphosphatemia risk.</p></sec><sec><title>Methods</title><p id="Par2">Data of patients with CKD discharged from the Department of Nephrology between January 2021 and December 2023 were retrospectively analyzed. Potential predictors were screened from an array of clinical variables using least absolute shrinkage and selection operator regression in conjunction with 10-fold cross-validation. A multivariate logistic regression model was constructed to identify independent risk factors for predicting hyperphosphatemia. The C-index, receiver operating characteristic curve, calibration curve, and decision curve analysis were used to evaluate model predictive power, discriminability, accuracy, and clinical utility. Internal validation was implemented through a comparison of results from a validation set and the entire dataset.</p></sec><sec><title>Results</title><p id="Par3">This study included 216 patients, with 134 (62.04%) individuals who developed hyperphosphatemia. Logistic regression revealed that hemoglobin, blood urea nitrogen, serum creatinine, and parathyroid hormone were independently correlated with hyperphosphatemia. The nomogram C-index was 0.916 (95% confidence interval [CI]: 0.872&#8211;0.961). The model demonstrated excellent discriminative ability in the independent validation set (area under the curve [AUC]&#8201;=&#8201;0.953, 95% CI: 0.909&#8211;0.998), with the full dataset analysis showing concordant results (AUC&#8201;=&#8201;0.923, 95% CI: 0.889&#8211;0.958). The decision and clinical impact curves showed the clinical value of our nomogram for patients with CKD and hyperphosphatemia.</p></sec><sec><title>Conclusions</title><p id="Par4">The nomogram model was highly accurate in identifying CKD subpopulations at an elevated risk of serum phosphorus metabolic disorders. Our model can be utilized for prospective monitoring and preventive intervention. Furthermore, through individualized risk assessments, the model can contribute to the development of customized treatment strategies that have the potential to markedly improve long-term prognosis.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12882-025-04445-0.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Hyperphosphatemia</kwd><kwd>Nomogram</kwd><kwd>Least absolute shrinkage and selection operator regression</kwd><kwd>Non-dialysis chronic kidney disease</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par5">Chronic kidney disease (CKD) is currently the 16th major determinant of mortality worldwide, affecting 8&#8211;16% of the global population. Its progressive shift toward younger demographics underscores its status as a pressing international public health issue [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. One notable complication of CKD is disordered phosphorus metabolism, often apparent in the early stages and worsening with disease progression. Elevated serum phosphorus levels, commonly known as hyperphosphatemia, serve as an initiating factor for other conditions such as skeletal disorders, cardiovascular diseases, and secondary hyperparathyroidism [<xref ref-type="bibr" rid="CR3">3</xref>]. In particular, hyperphosphatemia induces persistent skin pruritus that degrades quality of life and augments the risk of death from cardiovascular complications [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Owing to its knock-on effects, hyperphosphatemia is correlated with increased mortality in the CKD population [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par6">Dietary intake, intestinal absorption, and glomerular filtration rate (GFR) are all factors that regulate phosphorus metabolism [<xref ref-type="bibr" rid="CR8">8</xref>]. Almost all phosphate additives commonly added to processed foods can be absorbed by the gut [<xref ref-type="bibr" rid="CR9">9</xref>], increasing phosphate intake. Additionally, drug excipients often have a hidden phosphorus load, such as phosphate-containing antihypertensive sustained-release preparations and phosphate-containing acid suppressors [<xref ref-type="bibr" rid="CR10">10</xref>], exposing patients with CKD to the risk of double phosphorus intake.</p><p id="Par7">Currently, phosphorus-lowering treatment strategies include dietary phosphorus intake reduction, pharmacological interventions, and dialysis therapy [<xref ref-type="bibr" rid="CR11">11</xref>]. These options are less expensive than treating complications associated with hyperphosphatemia [<xref ref-type="bibr" rid="CR12">12</xref>]. Consequently, early and precise prediction of hyperphosphatemia risk in patients with CKD is clinically relevant but unfortunately underexplored, particularly among non-dialysis patients. Therefore, in this study, we developed a novel nomogram model to predict hyperphosphatemia risk in this patient population, aiming to identify clinical risk factors and facilitate personalized decision-making.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Data source and extraction</title><p id="Par8">The study included 1362 patients with CKD discharged between January 2021 and December 2023 from the Department of Nephrology, Nanping First Hospital Affiliated to Fujian Medical University. Cases were extracted from the inpatient electronic medical record system. Data included basic information (sex, age, alcohol consumption, and smoking history), concomitant diseases (e.g., hypertension, diabetes, and coronary atherosclerosis), therapeutic agents (e.g., dagagliptin, oral iron, human erythropoietin injection, roxadustat capsules, intestinal detoxifying agents, and renal care agents), and laboratory indicators (e.g., hemoglobin [HGB], electrolytes, renal function, alkaline phosphatase, ferritin, transferrin saturation, parathyroid hormone [PTH], and urinary protein levels).</p><p id="Par9">Patients were excluded if they met any of the following criteria: (1)&#8201;&lt;&#8201;18 years of age, (2) subjected to dialysis, (3) treated with phosphorus-lowering drugs (including patients who had previously taken and those who were currently taking phosphorus-lowering drugs), (4) had experienced gastrointestinal bleeding or acute left heart failure, (5) had prior parathyroid surgery, or (6) missing data. This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Nanping First Hospital affiliated to Fujian Medical University (approval number: NPSY202401007). Owing to the retrospective nature of the study, the requirement for written informed consent was waived.</p></sec><sec id="Sec4"><title>Definition of CKD stages and hyperphosphatemia</title><p id="Par10">According to the KDIGO Improving Global Outcomes guidelines, CKD is any abnormality of kidney structure or function with a negative health impact that persists for a minimum of 3 months. Kidney disease was categorized based on estimated GFR (eGFR) values, which correlate with progression risk [<xref ref-type="bibr" rid="CR13">13</xref>]: G1 (eGFR&#8201;&#8805;&#8201;90 mL/min/1.73 m<sup>2</sup>), G2 (60&#8211;89 mL/min/1.73 m<sup>2</sup>), G3a (45&#8211;59 mL/min/1.73 m<sup>2</sup>), G3b (30&#8211;44 mL/min/1.73 m<sup>2</sup>), G4 (15&#8211;29 mL/min/1.73 m<sup>2</sup>), and G5 (&lt;&#8201;15 mL/min/1.73 m<sup>2</sup>). Cystatin C was used to calculate eGFR in the hospital laboratory.</p><p id="Par11">Hyperphosphatemia was diagnosed when serum phosphorus exceeded 1.45 mmol/L. For patients with G3a&#8211;G5 stage CKD, the 2017 KDIGO guidelines recommend maintaining their blood phosphorus levels close to the normal range [<xref ref-type="bibr" rid="CR14">14</xref>].</p></sec><sec id="Sec5"><title>Statistical analysis</title><p id="Par12">SPSS version 29.0 (IBM Corp., Armonk, NY, USA) and RStudio version 4.4.2 (R Foundation for Statistical Computing, Vienna, Austria) were used for statistical analysis and mapping. The dataset was randomly partitioned into training and validation sets in a 7:3 ratio for comparative analysis. For continuous variables, normally distributed data are expressed as mean&#8201;&#177;&#8201;standard deviation and non-normally distributed data as median (range); categorical variables are represented as percentages. Intergroup comparisons were performed using Student&#8217;s <italic toggle="yes">t</italic>-test, chi-square test, or Mann-Whitney U test, with Fisher&#8217;s exact test applied when appropriate. To evaluate the relationship between variables, Pearson&#8217;s correlation analysis was performed for normally or near-normally distributed data, whereas Spearman&#8217;s correlation analysis was applied to non-normally distributed data. Thirty-two training set predictors were screened using least absolute shrinkage and selection operator (LASSO) regression and then used in a 10-fold cross-validation analysis to yield the minimum criteria (lambda.min). The optimal lambda was determined to be one standard error of the minimum criterion (Lambda.1se) [<xref ref-type="bibr" rid="CR15">15</xref>]. Higher lambda values enforce stronger regularization in the LASSO regression, driving more coefficients to zero and yielding a simpler model.</p><p id="Par13">Selected variables were included in a multivariate logistic regression to determine an independent risk score of hyperphosphatemia incidence. Subsequently, this score was used to establish a risk prediction model. Variance inflation factor (VIF) was used to assess multicollinearity. Significance was set at <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 (two-tailed test).</p><p id="Par14">The nomogram prediction model was developed in RStudio and internally validated with validation and full datasets. The discriminatory power of the model was assessed through receiver operating characteristic (ROC) analysis, demonstrating preferable forecast performance with an area under the curve (AUC) of &gt;&#8201;0.7. The Hosmer&#8211;Lemeshow test was used to evaluate model fit. Calibration curves were used to examine the applicability of the model in clinical settings through decision curve analysis (DCA). Subgroup analyses stratified by age, sex, and CKD stage were conducted to evaluate model robustness. The nomogram was constructed using the rms package, whereas ROC curves and corresponding AUC values were generated using the pROC package. Calibration curves were plotted using the val.prob() function in the rms package, and DCA curves were generated using the rmda package.</p></sec></sec><sec id="Sec6"><title>Results</title><sec id="Sec7"><title>Patient characteristics</title><p id="Par15">The final analysis included 216 patients (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Patients with hyperphosphatemia differed significantly from those with normal blood phosphorus levels in key epidemiological characteristics (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). After screening, we identified 134 (62.04%) cases of hyperphosphatemia among patients without dialysis. This cohort had a median age of 62 years (range 23.0&#8211;92.0 years) and was 60.2% male.</p><p id="Par16">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Schematic of the data collection process</p></caption><graphic id="d33e316" position="float" orientation="portrait" xlink:href="12882_2025_4445_Fig1_HTML.jpg"/></fig>
</p><p id="Par17">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Baseline demographic and disease characteristics of the dataset</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Variables</th><th align="left" colspan="1" rowspan="1">All cases<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;216)</th><th align="left" colspan="1" rowspan="1">Non-<break/>hyperphosphatemia<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;82)</th><th align="left" colspan="1" rowspan="1">Hyperphosphatemia<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;134)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Demographics (n, %)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Age (years)</td><td align="left" colspan="1" rowspan="1">62.0 (23&#8211;92)</td><td align="left" colspan="1" rowspan="1">63 (42&#8211;92)</td><td align="left" colspan="1" rowspan="1">61(23&#8211;87)</td><td align="left" colspan="1" rowspan="1">0.13</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Sex (male) (%)</td><td align="left" colspan="1" rowspan="1">130 (60.2)</td><td align="left" colspan="1" rowspan="1">59 (72.0)</td><td align="left" colspan="1" rowspan="1">71 (53.0)</td><td align="left" colspan="1" rowspan="1">0.006</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;BMI (kg/m<sup>2</sup>, %)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.002</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8195;18.5&#8211;25</td><td align="left" colspan="1" rowspan="1">147 (68.1)</td><td align="left" colspan="1" rowspan="1">57 (69.5)</td><td align="left" colspan="1" rowspan="1">90 (67.2)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8195;&lt;18.5</td><td align="left" colspan="1" rowspan="1">13 (6)</td><td align="left" colspan="1" rowspan="1">1 (1.2)</td><td align="left" colspan="1" rowspan="1">12 (9.0)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8195;25&#8211;30</td><td align="left" colspan="1" rowspan="1">46 (21.3)</td><td align="left" colspan="1" rowspan="1">24 (29.3)</td><td align="left" colspan="1" rowspan="1">22 (16.4)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8195;&#8805;30</td><td align="left" colspan="1" rowspan="1">10 (4.6)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">10 (7.5)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">&#8195;CKD stages (n, %)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8195;CKD stage 3</td><td align="left" colspan="1" rowspan="1">14 (6.5)</td><td align="left" colspan="1" rowspan="1">12 (14.6)</td><td align="left" colspan="1" rowspan="1">2 (1.5)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8195;CKD stage 4</td><td align="left" colspan="1" rowspan="1">46 (21.3)</td><td align="left" colspan="1" rowspan="1">37 (45.1)</td><td align="left" colspan="1" rowspan="1">9 (6.7)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8195;CKD stage 5</td><td align="left" colspan="1" rowspan="1">156 (72.2)</td><td align="left" colspan="1" rowspan="1">33 (40.2)</td><td align="left" colspan="1" rowspan="1">123 (91.8)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="5" rowspan="1">Underlying disease (n, %)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hypertension (%)</td><td align="left" colspan="1" rowspan="1">189 (87.5)</td><td align="left" colspan="1" rowspan="1">70 (85.4)</td><td align="left" colspan="1" rowspan="1">119 (88.8)</td><td align="left" colspan="1" rowspan="1">0.458</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Diabetes (%)</td><td align="left" colspan="1" rowspan="1">104 (48.1)</td><td align="left" colspan="1" rowspan="1">35 (42.7)</td><td align="left" colspan="1" rowspan="1">69 (51.5)</td><td align="left" colspan="1" rowspan="1">0.209</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Atherosclerosis (%)</td><td align="left" colspan="1" rowspan="1">160 (74.1)</td><td align="left" colspan="1" rowspan="1">56 (68.3)</td><td align="left" colspan="1" rowspan="1">104 (77.6)</td><td align="left" colspan="1" rowspan="1">0.129</td></tr><tr><td align="left" colspan="5" rowspan="1">Baseline laboratory tests (n, %)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;HGB (%)</td><td align="left" colspan="1" rowspan="1">175 (81)</td><td align="left" colspan="1" rowspan="1">52 (63.4)</td><td align="left" colspan="1" rowspan="1">123 (91.8)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;K (%)</td><td align="left" colspan="1" rowspan="1">28 (13)</td><td align="left" colspan="1" rowspan="1">2 (2.4)</td><td align="left" colspan="1" rowspan="1">26 (19.4)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Ca (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.03</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8195;2.1&#8211;2.5</td><td align="left" colspan="1" rowspan="1">103 (47.7)</td><td align="left" colspan="1" rowspan="1">48 (58.5)</td><td align="left" colspan="1" rowspan="1">55 (41.0)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8195;&lt;2.1</td><td align="left" colspan="1" rowspan="1">101 (46.8)</td><td align="left" colspan="1" rowspan="1">29 (35.4)</td><td align="left" colspan="1" rowspan="1">72 (53.7)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8195;&gt;2.5</td><td align="left" colspan="1" rowspan="1">12 (5.6)</td><td align="left" colspan="1" rowspan="1">5 (6.1)</td><td align="left" colspan="1" rowspan="1">7 (5.2)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">CO<sub>2</sub> (%)</td><td align="left" colspan="1" rowspan="1">113 (52.3)</td><td align="left" colspan="1" rowspan="1">25 (30.5)</td><td align="left" colspan="1" rowspan="1">88 (65.7)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">AG (%)</td><td align="left" colspan="1" rowspan="1">28 (13)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">28 (20.9)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">BUN (%)</td><td align="left" colspan="1" rowspan="1">123 (56.9)</td><td align="left" colspan="1" rowspan="1">16 (19.5)</td><td align="left" colspan="1" rowspan="1">107 (79.9)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Scr (mean, SD)</td><td align="left" colspan="1" rowspan="1">549.67 (283.39)</td><td align="left" colspan="1" rowspan="1">324.94 (146.88)</td><td align="left" colspan="1" rowspan="1">687.19 (257.86)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">UA (%)</td><td align="left" colspan="1" rowspan="1">139 (64.4)</td><td align="left" colspan="1" rowspan="1">45 (54.9)</td><td align="left" colspan="1" rowspan="1">94 (70.1)</td><td align="left" colspan="1" rowspan="1">0.023</td></tr><tr><td align="left" colspan="1" rowspan="1">TG (%)</td><td align="left" colspan="1" rowspan="1">78 (36.1)</td><td align="left" colspan="1" rowspan="1">32 (39.0)</td><td align="left" colspan="1" rowspan="1">46 (34.3)</td><td align="left" colspan="1" rowspan="1">0.486</td></tr><tr><td align="left" colspan="1" rowspan="1">TC (%)</td><td align="left" colspan="1" rowspan="1">58 (26.9)</td><td align="left" colspan="1" rowspan="1">20 (24.4)</td><td align="left" colspan="1" rowspan="1">38 (28.4)</td><td align="left" colspan="1" rowspan="1">0.523</td></tr><tr><td align="left" colspan="1" rowspan="1">TP (%)</td><td align="left" colspan="1" rowspan="1">96 (44.4)</td><td align="left" colspan="1" rowspan="1">35 (36.5)</td><td align="left" colspan="1" rowspan="1">61 (63.5)</td><td align="left" colspan="1" rowspan="1">0.684</td></tr><tr><td align="left" colspan="1" rowspan="1">ALB (%)</td><td align="left" colspan="1" rowspan="1">69 (31.9)</td><td align="left" colspan="1" rowspan="1">28 (34.1)</td><td align="left" colspan="1" rowspan="1">41 (30.6)</td><td align="left" colspan="1" rowspan="1">0.587</td></tr><tr><td align="left" colspan="1" rowspan="1">ALP (%)</td><td align="left" colspan="1" rowspan="1">40 (18.5)</td><td align="left" colspan="1" rowspan="1">9 (11.0)</td><td align="left" colspan="1" rowspan="1">31 (23.1)</td><td align="left" colspan="1" rowspan="1">0.026</td></tr><tr><td align="left" colspan="1" rowspan="1">SF (%)</td><td align="left" colspan="1" rowspan="1">110 (50.9)</td><td align="left" colspan="1" rowspan="1">39 (47.6)</td><td align="left" colspan="1" rowspan="1">71 (53.0)</td><td align="left" colspan="1" rowspan="1">0.439</td></tr><tr><td align="left" colspan="1" rowspan="1">TSAT (%)</td><td align="left" colspan="1" rowspan="1">31 (14.4)</td><td align="left" colspan="1" rowspan="1">15 (18.3)</td><td align="left" colspan="1" rowspan="1">16 (11.9)</td><td align="left" colspan="1" rowspan="1">0.196</td></tr><tr><td align="left" colspan="1" rowspan="1">PTH (mean, SD)</td><td align="left" colspan="1" rowspan="1">235.41 (202.05)</td><td align="left" colspan="1" rowspan="1">122.02 (84.31)</td><td align="left" colspan="1" rowspan="1">304.79 (221.11)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Urinary protein (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.045</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;-</td><td align="left" colspan="1" rowspan="1">38 (17.6)</td><td align="left" colspan="1" rowspan="1">20 (24.4)</td><td align="left" colspan="1" rowspan="1">18 (13.4)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;-+</td><td align="left" colspan="1" rowspan="1">14 (6.5)</td><td align="left" colspan="1" rowspan="1">8 (9.8)</td><td align="left" colspan="1" rowspan="1">6 (4.5)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;+</td><td align="left" colspan="1" rowspan="1">33 (15.3)</td><td align="left" colspan="1" rowspan="1">13 (15.9)</td><td align="left" colspan="1" rowspan="1">20 (14.9)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;++</td><td align="left" colspan="1" rowspan="1">72 (33.3)</td><td align="left" colspan="1" rowspan="1">26 (31.7)</td><td align="left" colspan="1" rowspan="1">46 (34.3)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;+++/++++</td><td align="left" colspan="1" rowspan="1">59 (27.3)</td><td align="left" colspan="1" rowspan="1">15 (18.3)</td><td align="left" colspan="1" rowspan="1">44 (32.8)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="5" rowspan="1">Combination therapy (n, %)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Daglizin (%)</td><td align="left" colspan="1" rowspan="1">8 (3.7)</td><td align="left" colspan="1" rowspan="1">6 (7.3)</td><td align="left" colspan="1" rowspan="1">2 (1.5)</td><td align="left" colspan="1" rowspan="1">0.028</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;ACEI/ARB (%)</td><td align="left" colspan="1" rowspan="1">51 (23.6)</td><td align="left" colspan="1" rowspan="1">21 (25.6)</td><td align="left" colspan="1" rowspan="1">30 (22.4)</td><td align="left" colspan="1" rowspan="1">0.588</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Oral iron (%)</td><td align="left" colspan="1" rowspan="1">165 (76.4)</td><td align="left" colspan="1" rowspan="1">54 (65.9)</td><td align="left" colspan="1" rowspan="1">111 (82.8)</td><td align="left" colspan="1" rowspan="1">0.004</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;EPO (%)</td><td align="left" colspan="1" rowspan="1">148 (68.5)</td><td align="left" colspan="1" rowspan="1">46 (56.1)</td><td align="left" colspan="1" rowspan="1">102 (76.1)</td><td align="left" colspan="1" rowspan="1">0.002</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Intestinal detoxification medication (%)</td><td align="left" colspan="1" rowspan="1">178 (82.4)</td><td align="left" colspan="1" rowspan="1">72 (87.8)</td><td align="left" colspan="1" rowspan="1">106 (79.1)</td><td align="left" colspan="1" rowspan="1">0.103</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Renal care drug (%)</td><td align="left" colspan="1" rowspan="1">63 (29.2)</td><td align="left" colspan="1" rowspan="1">27 (32.9)</td><td align="left" colspan="1" rowspan="1">36 (26.9)</td><td align="left" colspan="1" rowspan="1">0.342</td></tr><tr><td align="left" colspan="5" rowspan="1">Lifestyle (n, %)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Smoker (%)</td><td align="left" colspan="1" rowspan="1">13 (6)</td><td align="left" colspan="1" rowspan="1">4 (4.9)</td><td align="left" colspan="1" rowspan="1">9 (6.7)</td><td align="left" colspan="1" rowspan="1">0.581</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Drinker (%)</td><td align="left" colspan="1" rowspan="1">8 (3.7)</td><td align="left" colspan="1" rowspan="1">2 (2.4)</td><td align="left" colspan="1" rowspan="1">6 (4.5)</td><td align="left" colspan="1" rowspan="1">0.441</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: HGB, hemoglobin; AG, anion gap; BUN, blood urea nitrogen; Scr, serum creatinine; UA, uric acid; TG, triglyceride; TC, total cholesterol; TP, total protein; ALB, albumin; ALP, alkaline phosphatase; SF, serum ferritin; TSAT, transferrin saturation; PTH, parathyroid hormone; Oral iron, drug combination of Shengxuening tablets and ferrous sulfate tablets; EPO, human erythropoietin injection and roxadustat capsules; intestinal detoxification medication, drug combination of Niaoduqing granules and Shenshuaining tablets; Renal care drug, medication combining Bailing capsules and Shenyankangfu tablets</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec8"><title>Selection of clinical variables</title><p id="Par18">The training and validation sets demonstrated comparable baseline characteristics, with the exception of two clinical parameters: total cholesterol levels (TC, <italic toggle="yes">p</italic>&#8201;=&#8201;0.039) and ACEI/ARB usage (<italic toggle="yes">p</italic>&#8201;=&#8201;0.026), which showed a statistically significant difference (Additional file <xref rid="MOESM1" ref-type="media">3</xref>). Most variables in the training dataset demonstrated limited statistical interdependence (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). Variable selection was performed in two stages. First, five candidate predictive variables (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>; Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>): CKD stages, HGB, blood urea nitrogen (BUN), serum creatinine (Scr), and PTH were identified using LASSO regression with a 10-fold cross-validation (optimal regularization parameter Lambda.1se&#8201;=&#8201;0.09990857). To validate the stability of these selections and optimize model parsimony, we further refined the model using multivariable logistic regression with stepwise selection based on Akaike&#8217;s Information Criterion (AIC). The full model (all five variables) showed an AIC of 116.97, while the simplified model (excluding CKD stages) achieved a lower AIC of 113.62 (&#916;AIC&#8201;=&#8201;3.35), suggesting an improved fit with fewer parameters. A likelihood ratio test confirmed that excluding CKD stages did not significantly degrade the model fit (<italic toggle="yes">p</italic>&#8201;=&#8201;0.7252; Additional file <xref rid="MOESM1" ref-type="media">4</xref>). Although &#916;AIC&#8201;&gt;&#8201;2 might indicate a better performance, the non-significant P-value supported comparable predictive ability. Therefore, based on the principle of parsimony and statistical equivalence (<italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05), the final model retained four variables (HGB, BUN, Scr, and PTH) for subsequent analysis. VIF values were all &lt;&#8201;10 (Additional file <xref rid="MOESM1" ref-type="media">5</xref>), indicating that the included variables were not correlated and that the model was predictive and robust. The four independent risk factors associated with hyperphosphatemia were identified as HGB (odds ratio [OR]&#8201;=&#8201;5.64,95% confidence interval [CI]: 0.09&#8211;343.65, <italic toggle="yes">p</italic>&#8201;=&#8201;0.019), BUN (OR&#8201;=&#8201;3.67; 95% CI: 0.14&#8211;97.78, <italic toggle="yes">p</italic>&#8201;=&#8201;0.012), Scr (OR&#8201;=&#8201;1; 95% CI: 0.14&#8211;7.14, <italic toggle="yes">p</italic>&#8201;=&#8201;0.003), and PTH (OR&#8201;=&#8201;1.01; 95% CI: 0.14&#8211;7.19, <italic toggle="yes">p</italic>&#8201;=&#8201;0.013) (Additional file <xref rid="MOESM1" ref-type="media">6</xref>).</p><p id="Par19">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Correlation analysis among training dataset variables. CKD, staging of chronic kidney disease; HGB, hemoglobin; AG, anion gap; BUN, blood urea nitrogen; Scr, serum creatinine; UA, uric acid; TG, triglycerides; TC, total cholesterol; TP, total protein; ALB, albumin; ALP, alkaline phosphatase; SF, serum ferritin; TSAT, transferrin saturation; PTH, parathyroid hormone; Oral_iron, medication including Shengxuening tablets and ferrous sulfate tablets; EPO, human erythropoietin injection and roxadustat capsules; intestinal_detoxification_medication, combination of Niaoduqing granules and Shenshuaining tablets; Renal_care_drug, combination of Bailing capsules and Shenyankangfu tablets</p></caption><graphic id="d33e937" position="float" orientation="portrait" xlink:href="12882_2025_4445_Fig2_HTML.jpg"/></fig>
</p><p id="Par20">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>LASSO regression analysis of key variables associated with hyperphosphatemia in the training dataset</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Variables</th><th align="left" colspan="1" rowspan="1">Coefficient</th><th align="left" colspan="1" rowspan="1">Lambda.1se</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">CKD stages</td><td char="." align="char" colspan="1" rowspan="1">0.120781768</td><td char="." align="char" colspan="1" rowspan="1">0.09990857</td></tr><tr><td align="left" colspan="1" rowspan="1">HGB</td><td char="." align="char" colspan="1" rowspan="1">0.159732852</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">BUN</td><td char="." align="char" colspan="1" rowspan="1">0.808516247</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Scr</td><td char="." align="char" colspan="1" rowspan="1">0.001969694</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">PTH</td><td char="." align="char" colspan="1" rowspan="1">0.000738656</td><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p>Abbreviations: HGB, hemoglobin; BUN, blood urea nitrogen; Scr, serum creatinine; PTH, parathyroid hormone</p></table-wrap-foot></table-wrap>
</p><p id="Par21">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Clinical variables were selected using LASSO regression. Dashed lines represent lambda.min (left) and lambda.1se (right)</p></caption><graphic id="d33e1001" position="float" orientation="portrait" xlink:href="12882_2025_4445_Fig3_HTML.jpg"/></fig>
</p></sec><sec id="Sec9"><title>Model construction and validation</title><p id="Par22">Based on the four independent risk scores, we established a nomogram model to predict hyperphosphatemia risk in non-dialysis patients with CKD (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). We also developed a complementary web-based dynamic nomogram (<ext-link ext-link-type="uri" xlink:href="https://lcyx.shinyapps.io/DynNomapp/">https://lcyx.shinyapps.io/DynNomapp/</ext-link>; Additional file <xref rid="MOESM1" ref-type="media">1</xref>) that enables clinicians to obtain instant risk projections. The nomogram model demonstrated robust discriminative ability (C-index&#8201;=&#8201;0.916, 95% CI: 0.872&#8211;0.961; Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>a), with sensitivity meeting prespecified clinical thresholds (AUC&#8201;&gt;&#8201;0.7). Comparative ROC analysis revealed that the nomogram model outperformed individual predictors (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>b). Calibration plots (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>c) showed that the predicted probabilities aligned optimally with the observed outcomes (Hosmer&#8211;Lemeshow test: <italic toggle="yes">p</italic>&#8201;=&#8201;0.979). The DCA curves supported the clinical utility of the nomogram model. Compared with any single variable, the nomogram model offered the greatest net benefit (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>d). The model demonstrated excellent discriminative performance in the independent validation set (AUC&#8201;=&#8201;0.953, 95% CI: 0.909&#8211;0.998; Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>e&#8211;g), with all validation metrics confirming robust discrimination, calibration, and clinical utility. For completeness, analysis of the full dataset (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>h&#8211;j) showed concordant but slightly lower performance (AUC&#8201;=&#8201;0.923, 95% CI: 0.889&#8211;0.958), which we have presented as supplementary evidence of the model consistency. Subgroup analyses revealed consistently robust predictive performance across key demographic and clinical subgroups, including age categories (AUC&#8201;=&#8201;0.958 and 0.950 for &#8805;&#8201;65 years and &lt;&#8201;65 years, respectively), sex-based divisions (female and male, AUC&#8201;=&#8201;0.926 and 0.925, respectively), and CKD stages (4 and 5, AUC&#8201;=&#8201;0.800 and 0.921, respectively) (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>; Additional file <xref rid="MOESM1" ref-type="media">2</xref>).</p><p id="Par23">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Clinical variables were ranked according to the magnitude of their regression coefficients&#8217; standard deviations (SD). * indicates that four variables (BUN, HGB, Scr, and PTH) were significant in the final model. Frequency distribution of categorical variables is represented by the size of the block (larger block equals more people). Curves represent the distribution of values for continuous variables. Predictive nomogram for hyperphosphatemia risk. Red dots indicate the fifth observation in the training dataset, matched to its corresponding values per variable: BUN&#8201;&gt;&#8201;20, HGB&#8201;&lt;&#8201;110, Scr&#8201;=&#8201;662.03, PTH&#8201;=&#8201;332.2, and total points&#8201;=&#8201;158. Based on these data, the nomogram predicted a hyperphosphatemia risk of 0.956. The red horizontal line indicates a confidence interval of 0.879,0.985. BUN, blood urea nitrogen; HGB, hemoglobin; Scr, serum creatinine; PTH, parathyroid hormone</p></caption><graphic id="d33e1054" position="float" orientation="portrait" xlink:href="12882_2025_4445_Fig4_HTML.jpg"/></fig>
</p><p id="Par24">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Evaluation and validation of the hyperphosphatemia nomogram model. (<bold>a</bold>) Receiver operating characteristic (ROC) curve of the training set. Area under the curve (AUC) was 0.916. (<bold>b</bold>) Comparison of the nomogram area AUC and single predictive factor AUC. (<bold>c</bold>) Calibration curve of the hyperphosphatemia prediction model is represented by the dashed diagonal line. Solid black lines indicate an ideal nomogram model. (<bold>d</bold>) Analysis of the nomogram model (DCA). (<bold>e</bold>) Internal validation of the nomogram model using the validation dataset. (<bold>f</bold>) Internal validation of the nomogram model with the full sample dataset</p></caption><graphic id="d33e1084" position="float" orientation="portrait" xlink:href="12882_2025_4445_Fig5_HTML.jpg"/></fig>
</p><p id="Par25">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Stratified ROC curve evaluation</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Subgroups</th><th align="left" colspan="1" rowspan="1">AUC</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (years)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Age&#8201;&#8805;&#8201;65</td><td char="." align="char" colspan="1" rowspan="1">0.958</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Age&#8201;&lt;&#8201;65</td><td char="." align="char" colspan="1" rowspan="1">0.950</td></tr><tr><td align="left" colspan="1" rowspan="1">Sex</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Female</td><td char="." align="char" colspan="1" rowspan="1">0.926</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Male</td><td char="." align="char" colspan="1" rowspan="1">0.925</td></tr><tr><td align="left" colspan="1" rowspan="1">CKD stages</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;CKD stage 4</td><td char="." align="char" colspan="1" rowspan="1">0.800</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;CKD stage 5</td><td char="." align="char" colspan="1" rowspan="1">0.921</td></tr></tbody></table></table-wrap>
</p></sec></sec><sec id="Sec10"><title>Discussion</title><p id="Par26">Dysfunction in blood phosphorus metabolism becomes apparent at CKD stage 3 and then progressively increases in prevalence, with hyperphosphatemia being a frequent complication during stages 4 and 5 [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. In this study, the incidence of hyperphosphatemia in patients with non-dialysis CKD was 62.04%, with two stage 3 cases (1.5%), nine stage 4 cases (6.7%), and 123 stage 5 cases (91.8%). The overall trend in hyperphosphatemia incidence was similar to prior reports [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Our study successfully identified independent risk factors for hyperphosphatemia, which we applied to the development and validation of a predictive nomogram. We conducted stratified analyses based on age, sex, and CKD stage, demonstrating the high predictive performance of our nomogram in different patient subpopulations. Hence, our model can facilitate early intervention and improve disease management.</p><p id="Par27">The risk of hyperphosphatemia in patients with non-dialysis CKD is understudied. Furthermore, clinical studies have largely focused on patients who require dialysis (including peritoneal dialysis [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>] and hemodialysis [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]). To address this gap, we reassessed risk factors via an analysis of patient profiles, laboratory markers, and combination therapy. The resultant hyperphosphatemia nomogram identified HGB, BUN, Scr, and PTH as independent risk factors for hyperphosphatemia in patients with non-dialysis CKD. In contrast to the earlier analysis, we did not find a correlation between hyperphosphatemia and sex, age, or obesity. This inconsistency could be attributed to the relatively small number of participants in our study. Nevertheless, our clinically accessible nomogram prediction model used the four risk factors successfully and estimated hyperphosphatemia risk accurately. The model exhibited a high C-index and strong goodness-of-fit (<italic toggle="yes">p</italic>&#8201;=&#8201;0.979), providing robust and stable discriminative ability between different subgroups of non-dialysis patients with CKD.</p><p id="Par28">The four main independent risk factors for hyperphosphatemia are all physiological measures directly linked to kidney function. For example, elevated Scr levels reflect aggravated impairment of kidney function, specifically a lower phosphorus-filtering capacity that hampers blood phosphorus excretion. As GFR progressively declines, mechanisms related to maintaining phosphorus homeostasis are compromised, increasing the risk of hyperphosphatemia [<xref ref-type="bibr" rid="CR22">22</xref>]. Our results are consistent with those of previous studies that report a correlation between hyperphosphatemia and Scr [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par29">Furthermore, our findings align with previous research establishing a substantial association between hyperphosphatemia and BUN [<xref ref-type="bibr" rid="CR24">24</xref>]. Similar to Scr, this association is likely not a direct causal relationship but a reflection of severe kidney impairment. BUN and Scr are clinically established biomarkers for renal function, serving as key parameters in estimating GFR and nephron impairment. To summarize, when patients with CKD develop renal impairment or even renal failure, the decreased ability of kidneys to expel phosphorus greatly increases hyperphosphatemia risk while elevating Scr and BUN levels.</p><p id="Par30">The association of HGB and PTH levels with hyperphosphatemia is also consistent with prior reports [<xref ref-type="bibr" rid="CR21">21</xref>]. Fluctuations in HGB are also a clinical marker of anemia severity, and the association between anemia and hyperphosphatemia is well-established. Recent studies indicate that low hemoglobin levels may reflect an underlying inflammatory state, which could disrupt fibroblast growth factor-23 (FGF-23) regulation and impair phosphorus metabolism. This inflammatory milieu may establish a vicious cycle in which anemia exacerbates mineral metabolism disorders, while the resulting hyperphosphatemia may further aggravate anemia through enhanced FGF-23 activity [<xref ref-type="bibr" rid="CR25">25</xref>]. In patients with CKD, impaired renal function diminishes erythropoietin production, and synergistically with secondary hyperparathyroidism accelerate the progression of renal anemia. During the early stages, residual renal function can maintain phosphorus homeostasis despite slightly elevated PTH and FGF-23 levels. However, as kidney function declines, the increase in blood phosphorus level upregulates PTH, which in turn promotes phosphorus release from bone tissue to the blood. Hyperphosphatemia risk greatly increases under this vicious cycle during CKD progression [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par31">This study has certain limitations. First, we used a retrospective design that naturally resulted in some missing information relevant to our analysis. Second, we used internal verification to assess the predictive performance of the model. Third, our fairly small sample size contributed to extremely wide confidence intervals (CIs) for some reported results (e.g., HGB [OR&#8201;=&#8201;5.64, 95% CI: 0.09&#8211;343.65, <italic toggle="yes">p</italic>&#8201;=&#8201;0.019]), which restricts the broader applicability of the model. A practical and effective strategy would involve conducting multicenter collaborative studies to ensure an adequate sample size for external validation, thereby mitigating the issue of excessively wide confidence intervals. To strengthen the clinical applicability of our nomogram and the identified risk factors, future investigations should explore multi-regional and multicenter collaborations to increase the sample size and validate our results. Additionally, further research could include patients undergoing phosphate-lowering therapy to assess the predictive performance of this model in treated populations.</p></sec><sec id="Sec11"><title>Conclusions</title><p id="Par32">We identified HGB, BUN, Scr, and PTH as four independent risk factors of hyperphosphatemia in patients with non-dialysis CKD. We then used these findings to develop and validate a practical nomogram model for risk assessment. Integration of this model into clinical decision-making can aid in optimizing phosphate management in patients with CKD, particularly the understudied subpopulation of non-dialysis cases. Although multicenter prospective studies are warranted to evaluate the external validity and clinical applicability of the model, our study findings demonstrate the potential to lower the risk of complications associated with hyperphosphatemia.</p></sec><sec id="Sec12" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xlink:href="12882_2025_4445_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>XZ: study design, data collection and analysis, and manuscript drafting. CZ: Study design and manuscript drafting. QS and DL: Data collection and analysis. SW: Data analyses. ZJ and ZW: Study design and manuscript revision. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request (e-mail: 53018640@qq.com).</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par33">This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Nanping First Hospital affiliated to Fujian Medical University (approval number: NPSY202401007). Owing to the retrospective nature of the study, the requirement for written informed consent was waived.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par34">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par35">The authors declare no competing interests.</p></notes></notes><glossary><title>Abbreviations</title><def-list><def-item><term>CKD</term><def><p id="Par36">Chronic kidney disease</p></def></def-item><def-item><term>AUC</term><def><p id="Par37">Area under the curve</p></def></def-item><def-item><term>CI</term><def><p id="Par38">Confidence interval</p></def></def-item><def-item><term>LASSO</term><def><p id="Par39">Least absolute shrinkage and selection operator</p></def></def-item><def-item><term>GFR</term><def><p id="Par40">Glomerular filtration rate</p></def></def-item><def-item><term>eGFR</term><def><p id="Par41">Estimated GFR values</p></def></def-item><def-item><term>AIC</term><def><p id="Par42">Akaike&#8217;s Information Criterion</p></def></def-item><def-item><term>VIF</term><def><p id="Par43">Variance inflation factor</p></def></def-item><def-item><term>ROC</term><def><p id="Par44">Receiver operating characteristic</p></def></def-item><def-item><term>DCA</term><def><p id="Par45">Decision curve analysis</p></def></def-item><def-item><term>OR</term><def><p id="Par46">Odds ratio</p></def></def-item><def-item><term>HGB</term><def><p id="Par47">Hemoglobin</p></def></def-item><def-item><term>AG</term><def><p id="Par48">Anion gap</p></def></def-item><def-item><term>BUN</term><def><p id="Par49">Blood urea nitrogen</p></def></def-item><def-item><term>Scr</term><def><p id="Par50">Serum creatinine</p></def></def-item><def-item><term>UA</term><def><p id="Par51">Uric acid</p></def></def-item><def-item><term>TG</term><def><p id="Par52">Triglyceride</p></def></def-item><def-item><term>TC</term><def><p id="Par53">Total cholesterol</p></def></def-item><def-item><term>TP</term><def><p id="Par54">Total protein</p></def></def-item><def-item><term>ALB</term><def><p id="Par55">Albumin</p></def></def-item><def-item><term>ALP</term><def><p id="Par56">Alkaline phosphatase</p></def></def-item><def-item><term>SF</term><def><p id="Par57">Serum ferritin</p></def></def-item><def-item><term>TSAT</term><def><p id="Par58">Transferrin saturation</p></def></def-item><def-item><term>PTH</term><def><p id="Par59">Parathyroid hormone</p></def></def-item><def-item><term>EPO</term><def><p id="Par60">Human erythropoietin injection and roxadustat capsules</p></def></def-item><def-item><term>FGF-23</term><def><p id="Par61">Fibroblast growth factor-23</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>TK</given-names></name><name name-style="western"><surname>Knicely</surname><given-names>DH</given-names></name><name name-style="western"><surname>Grams</surname><given-names>ME</given-names></name></person-group><article-title>Chronic kidney disease diagnosis and management: a review</article-title><source>JAMA</source><year>2019</year><volume>322</volume><fpage>1294</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1001/jama.2019.14745</pub-id><pub-id pub-id-type="pmid">31573641</pub-id><pub-id pub-id-type="pmcid">PMC7015670</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA. 2019;322:1294&#8211;304. 10.1001/jama.2019.14745.<pub-id pub-id-type="pmid">31573641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2019.14745</pub-id><pub-id pub-id-type="pmcid">PMC7015670</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><collab>GBD Chronic Kidney Disease Collaboration</collab></person-group><article-title>Global, regional, and National burden of chronic kidney disease, 1990&#8211;2017: a systematic analysis for the global burden of disease study 2017</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>709</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30045-3</pub-id><pub-id pub-id-type="pmid">32061315</pub-id><pub-id pub-id-type="pmcid">PMC7049905</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">GBD Chronic Kidney Disease Collaboration. Global, regional, and National burden of chronic kidney disease, 1990&#8211;2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020;395:709&#8211;33. 10.1016/S0140-6736(20)30045-3.<pub-id pub-id-type="pmid">32061315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30045-3</pub-id><pub-id pub-id-type="pmcid">PMC7049905</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ritter</surname><given-names>CS</given-names></name><name name-style="western"><surname>Slatopolsky</surname><given-names>E</given-names></name></person-group><article-title>Phosphate toxicity in CKD: the killer among Us</article-title><source>Clin J Am Soc Nephrol</source><year>2016</year><volume>11</volume><fpage>10881100</fpage><pub-id pub-id-type="doi">10.2215/CJN.11901115</pub-id><pub-id pub-id-type="pmcid">PMC4891758</pub-id><pub-id pub-id-type="pmid">26912542</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Ritter CS, Slatopolsky E. Phosphate toxicity in CKD: the killer among Us. Clin J Am Soc Nephrol. 2016;11:10881100. 10.2215/CJN.11901115.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2215/CJN.11901115</pub-id><pub-id pub-id-type="pmcid">PMC4891758</pub-id><pub-id pub-id-type="pmid">26912542</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kendrick</surname><given-names>J</given-names></name><name name-style="western"><surname>Chonchol</surname><given-names>M</given-names></name></person-group><article-title>The role of phosphorus in the development and progression of vascular calcification</article-title><source>Am J Kidney Dis</source><year>2011</year><volume>58</volume><fpage>826</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2011.07.020</pub-id><pub-id pub-id-type="pmid">21956015</pub-id><pub-id pub-id-type="pmcid">PMC3199354</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Kendrick J, Chonchol M. The role of phosphorus in the development and progression of vascular calcification. Am J Kidney Dis. 2011;58:826&#8211;34. 10.1053/j.ajkd.2011.07.020.<pub-id pub-id-type="pmid">21956015</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.ajkd.2011.07.020</pub-id><pub-id pub-id-type="pmcid">PMC3199354</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kestenbaum</surname><given-names>B</given-names></name><name name-style="western"><surname>Sampson</surname><given-names>JN</given-names></name><name name-style="western"><surname>Rudser</surname><given-names>KD</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Seliger</surname><given-names>SL</given-names></name><name name-style="western"><surname>Young</surname><given-names>B</given-names></name><etal/></person-group><article-title>Serum phosphate levels and mortality risk among people with chronic kidney disease</article-title><source>J Am Soc Nephrol</source><year>2005</year><volume>16</volume><fpage>520</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1681/ASN.2004070602</pub-id><pub-id pub-id-type="pmid">15615819</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16:520&#8211;8. 10.1681/ASN.2004070602.<pub-id pub-id-type="pmid">15615819</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.2004070602</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akram</surname><given-names>MA</given-names></name><name name-style="western"><surname>Hyperphosphatemia</surname></name></person-group><article-title>The hidden killer in chronic kidney disease</article-title><source>Saudi Med J</source><year>2015</year><volume>36</volume><fpage>13</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.15537/smj.2015.1.9843</pub-id><pub-id pub-id-type="pmid">25629999</pub-id><pub-id pub-id-type="pmcid">PMC4362181</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Akram MA, Hyperphosphatemia. The hidden killer in chronic kidney disease. Saudi Med J. 2015;36:13&#8211;9. 10.15537/smj.2015.1.9843.<pub-id pub-id-type="pmid">25629999</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15537/smj.2015.1.9843</pub-id><pub-id pub-id-type="pmcid">PMC4362181</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Covic</surname><given-names>A</given-names></name><name name-style="western"><surname>Rastogi</surname><given-names>A</given-names></name></person-group><article-title>Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence</article-title><source>BMC Nephrol</source><year>2013</year><volume>14</volume><fpage>153</fpage><pub-id pub-id-type="doi">10.1186/1471-2369-14-153</pub-id><pub-id pub-id-type="pmid">23865421</pub-id><pub-id pub-id-type="pmcid">PMC3728082</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Covic A, Rastogi A. Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence. BMC Nephrol. 2013;14:153. 10.1186/1471-2369-14-153.<pub-id pub-id-type="pmid">23865421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2369-14-153</pub-id><pub-id pub-id-type="pmcid">PMC3728082</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaneko</surname><given-names>I</given-names></name><name name-style="western"><surname>Tatsumi</surname><given-names>S</given-names></name><name name-style="western"><surname>Segawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Miyamoto</surname><given-names>KI</given-names></name></person-group><article-title>Control of phosphate balance by the kidney and intestine</article-title><source>Clin Exp Nephrol</source><year>2017</year><volume>21</volume><issue>Suppl 1</issue><fpage>21</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1007/s10157-016-1359-4</pub-id><pub-id pub-id-type="pmid">27900568</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Kaneko I, Tatsumi S, Segawa H, Miyamoto KI. Control of phosphate balance by the kidney and intestine. Clin Exp Nephrol. 2017;21(Suppl 1):21&#8211;6. 10.1007/s10157-016-1359-4.<pub-id pub-id-type="pmid">27900568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10157-016-1359-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hannedouche</surname><given-names>T</given-names></name><name name-style="western"><surname>Fouque</surname><given-names>D</given-names></name><name name-style="western"><surname>Joly</surname><given-names>D</given-names></name></person-group><article-title>Metabolic complications in chronic kidney disease: hyperphosphatemia, hyperkalemia and anemia</article-title><source>Nephrol Ther</source><year>2018</year><volume>14</volume><fpage>S1617</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/S1769-7255(18)30647-3</pub-id><pub-id pub-id-type="pmid">30473062</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Hannedouche T, Fouque D, Joly D. Metabolic complications in chronic kidney disease: hyperphosphatemia, hyperkalemia and anemia. Nephrol Ther. 2018;14:S1617&#8211;25. 10.1016/S1769-7255(18)30647-3.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1769-7255(18)30647-3</pub-id><pub-id pub-id-type="pmid">30473062</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cupisti</surname><given-names>A</given-names></name><name name-style="western"><surname>Moriconi</surname><given-names>D</given-names></name><name name-style="western"><surname>D&#8217;Alessandro</surname><given-names>C</given-names></name><name name-style="western"><surname>Verde</surname><given-names>F</given-names></name><name name-style="western"><surname>Marchini</surname><given-names>M</given-names></name><name name-style="western"><surname>Saba</surname><given-names>A</given-names></name><name name-style="western"><surname>Egidi</surname><given-names>MF</given-names></name></person-group><article-title>The extra-phosphate intestinal load from medications: is it a real concern?</article-title><source>J Nephrol</source><year>2016</year><volume>29</volume><fpage>857</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1007/s40620-016-0306-5</pub-id><pub-id pub-id-type="pmid">27084800</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Cupisti A, Moriconi D, D&#8217;Alessandro C, Verde F, Marchini M, Saba A, Egidi MF. The extra-phosphate intestinal load from medications: is it a real concern? J Nephrol. 2016;29:857&#8211;62. 10.1007/s40620-016-0306-5.<pub-id pub-id-type="pmid">27084800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40620-016-0306-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><collab>Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group</collab></person-group><article-title>KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).&#8194;Kidney</article-title><source>Int Suppl</source><year>2017</year><volume>7</volume><fpage>1</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.kisu.2017.04.001</pub-id><pub-id pub-id-type="pmcid">PMC6340919</pub-id><pub-id pub-id-type="pmid">30675420</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).&#8194;Kidney. Int Suppl. 2017;7:1&#8211;59. 10.1016/j.kisu.2017.04.001.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.kisu.2017.04.001</pub-id><pub-id pub-id-type="pmcid">PMC6340919</pub-id><pub-id pub-id-type="pmid">30675420</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jie</surname><given-names>W</given-names></name><name name-style="western"><surname>Yao</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zou</surname><given-names>K</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name></person-group><article-title>Analysis of the economic burden of chronic kidney disease with comorbidities among patients in xuzhou, China</article-title><source>Int J Public Health</source><year>2024</year><volume>69</volume><fpage>1607000</fpage><pub-id pub-id-type="doi">10.3389/ijph.2024.1607000</pub-id><pub-id pub-id-type="pmid">39027012</pub-id><pub-id pub-id-type="pmcid">PMC11254622</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Jie W, Yao M, Wang M, Wang Y, Jia Y, Liu Y, Zou K, Sun X. Analysis of the economic burden of chronic kidney disease with comorbidities among patients in xuzhou, China. Int J Public Health. 2024;69:1607000. 10.3389/ijph.2024.1607000.<pub-id pub-id-type="pmid">39027012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/ijph.2024.1607000</pub-id><pub-id pub-id-type="pmcid">PMC11254622</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><collab>Kidney Disease</collab></person-group><article-title>Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease</article-title><source>Kidney Int Suppl</source><year>2013</year><volume>3</volume><fpage>1</fpage><lpage>150</lpage></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Kidney Disease. Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1&#8211;150.</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isakova</surname><given-names>T</given-names></name><name name-style="western"><surname>Nickolas</surname><given-names>TL</given-names></name><name name-style="western"><surname>Denburg</surname><given-names>M</given-names></name><name name-style="western"><surname>Yarlagadda</surname><given-names>S</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>DE</given-names></name><name name-style="western"><surname>Guti&#233;rrez</surname><given-names>OM</given-names></name><name name-style="western"><surname>Bansal</surname><given-names>V</given-names></name><name name-style="western"><surname>Rosas</surname><given-names>SE</given-names></name><name name-style="western"><surname>Nigwekar</surname><given-names>S</given-names></name><name name-style="western"><surname>Yee</surname><given-names>J</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>H</given-names></name></person-group><article-title>KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney Disease-Mineral and bone disorder (CKD-MBD)</article-title><source>Am J Kidney Dis</source><year>2017</year><volume>70</volume><fpage>737</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2017.07.019</pub-id><pub-id pub-id-type="pmid">28941764</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Guti&#233;rrez OM, Bansal V, Rosas SE, Nigwekar S, Yee J, Kramer H. KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney Disease-Mineral and bone disorder (CKD-MBD). Am J Kidney Dis. 2017;70:737&#8211;51. 10.1053/j.ajkd.2017.07.019.<pub-id pub-id-type="pmid">28941764</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.ajkd.2017.07.019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Hastie</surname><given-names>T</given-names></name><name name-style="western"><surname>Tibshirani</surname><given-names>R</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>J</given-names></name></person-group><source>The elements of statistical learning: data mining, inference, and prediction</source><year>2008</year><edition>2</edition><publisher-loc>New York</publisher-loc><publisher-name>Springer</publisher-name></element-citation><mixed-citation id="mc-CR15" publication-type="book">Hastie T, Tibshirani R, Friedman J. The elements of statistical learning: data mining, inference, and prediction. 2nd ed. New York: Springer; 2008.</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsuchiya</surname><given-names>K</given-names></name><name name-style="western"><surname>Akihisa</surname><given-names>T</given-names></name></person-group><article-title>The importance of phosphate control in chronic kidney disease</article-title><source>Nutrients</source><year>2021</year><volume>13</volume><fpage>1670</fpage><pub-id pub-id-type="doi">10.3390/nu13051670</pub-id><pub-id pub-id-type="pmid">34069053</pub-id><pub-id pub-id-type="pmcid">PMC8156430</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Tsuchiya K, Akihisa T. The importance of phosphate control in chronic kidney disease. Nutrients. 2021;13:1670. 10.3390/nu13051670.<pub-id pub-id-type="pmid">34069053</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu13051670</pub-id><pub-id pub-id-type="pmcid">PMC8156430</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>DD</given-names></name><name name-style="western"><surname>Vachhani</surname><given-names>U</given-names></name><name name-style="western"><surname>Rajput</surname><given-names>A</given-names></name><name name-style="western"><surname>Raghavani</surname><given-names>P</given-names></name><name name-style="western"><surname>Parchwani</surname><given-names>DN</given-names></name><name name-style="western"><surname>Dholariya</surname><given-names>S</given-names></name></person-group><article-title>Analysis of the prevalence and severity of dysregulated bone mineral homeostasis in nondialyzed chronic kidney disease patients</article-title><source>J Lab Physicians</source><year>2021</year><volume>14</volume><fpage>144</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1055/s-0041-1732495</pub-id><pub-id pub-id-type="pmid">35982879</pub-id><pub-id pub-id-type="pmcid">PMC9381320</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Patel DD, Vachhani U, Rajput A, Raghavani P, Parchwani DN, Dholariya S. Analysis of the prevalence and severity of dysregulated bone mineral homeostasis in nondialyzed chronic kidney disease patients. J Lab Physicians. 2021;14:144&#8211;50. 10.1055/s-0041-1732495.<pub-id pub-id-type="pmid">35982879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0041-1732495</pub-id><pub-id pub-id-type="pmcid">PMC9381320</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imtiaz</surname><given-names>R</given-names></name><name name-style="western"><surname>Hawken</surname><given-names>S</given-names></name><name name-style="western"><surname>McCormick</surname><given-names>BB</given-names></name><name name-style="western"><surname>Leung</surname><given-names>S</given-names></name><name name-style="western"><surname>Hiremath</surname><given-names>S</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>DL</given-names></name></person-group><article-title>Diabetes mellitus and younger age are risk factors for hyperphosphatemia in peritoneal Dialysis patients</article-title><source>Nutrients</source><year>2017</year><volume>9</volume><fpage>152</fpage><pub-id pub-id-type="doi">10.3390/nu9020152</pub-id><pub-id pub-id-type="pmid">28218647</pub-id><pub-id pub-id-type="pmcid">PMC5331583</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Imtiaz R, Hawken S, McCormick BB, Leung S, Hiremath S, Zimmerman DL. Diabetes mellitus and younger age are risk factors for hyperphosphatemia in peritoneal Dialysis patients. Nutrients. 2017;9:152. 10.3390/nu9020152.<pub-id pub-id-type="pmid">28218647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu9020152</pub-id><pub-id pub-id-type="pmcid">PMC5331583</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name></person-group><article-title>Prevalence and factors associated with hyperphosphatemia in continuous ambulatory peritoneal Dialysis patients: a cross-sectional study</article-title><source>Front Med (Lausanne)</source><year>2023</year><volume>10</volume><fpage>1217890</fpage><pub-id pub-id-type="doi">10.3389/fmed.2023.1217890</pub-id><pub-id pub-id-type="pmid">37457587</pub-id><pub-id pub-id-type="pmcid">PMC10349380</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Yin X, Zhang F, Shi Y. Prevalence and factors associated with hyperphosphatemia in continuous ambulatory peritoneal Dialysis patients: a cross-sectional study. Front Med (Lausanne). 2023;10:1217890. 10.3389/fmed.2023.1217890.<pub-id pub-id-type="pmid">37122336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2023.1142013</pub-id><pub-id pub-id-type="pmcid">PMC10140417</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>J</given-names></name><name name-style="western"><surname>Jeon-Slaughter</surname><given-names>H</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>H</given-names></name><name name-style="western"><surname>Patel</surname><given-names>J</given-names></name><name name-style="western"><surname>Sambandam</surname><given-names>KK</given-names></name><name name-style="western"><surname>Shastri</surname><given-names>S</given-names></name><name name-style="western"><surname>Van Buren</surname><given-names>PN</given-names></name></person-group><article-title>Hyperphosphatemia and its relationship with blood pressure, vasoconstriction, and endothelial cell dysfunction in hypertensive Hemodialysis patients</article-title><source>BMC Nephrol</source><year>2022</year><volume>23</volume><fpage>291</fpage><pub-id pub-id-type="doi">10.1186/s12882-022-02918-0</pub-id><pub-id pub-id-type="pmid">35999520</pub-id><pub-id pub-id-type="pmcid">PMC9396889</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Jung J, Jeon-Slaughter H, Nguyen H, Patel J, Sambandam KK, Shastri S, Van Buren PN. Hyperphosphatemia and its relationship with blood pressure, vasoconstriction, and endothelial cell dysfunction in hypertensive Hemodialysis patients. BMC Nephrol. 2022;23:291. 10.1186/s12882-022-02918-0.<pub-id pub-id-type="pmid">35999520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12882-022-02918-0</pub-id><pub-id pub-id-type="pmcid">PMC9396889</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rabbani</surname><given-names>SA</given-names></name><name name-style="western"><surname>BS</surname><given-names>S</given-names></name><name name-style="western"><surname>Rao</surname><given-names>PGM</given-names></name><name name-style="western"><surname>Kurian</surname><given-names>MT</given-names></name><name name-style="western"><surname>Essawy</surname><given-names>BE</given-names></name></person-group><article-title>Hyperphosphatemia in end stage renal disease: prevalence and patients characteristics of multiethnic population of united Arab Emirates</article-title><source>Int J Pharm Pharm Sci</source><year>2017</year><volume>9</volume><fpage>283</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.22159/ijpps.2017v9i12.22425</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Rabbani SA, BS S, Rao PGM, Kurian MT, Essawy BE. Hyperphosphatemia in end stage renal disease: prevalence and patients characteristics of multiethnic population of united Arab Emirates. Int J Pharm Pharm Sci. 2017;9:283&#8211;7. 10.22159/ijpps.2017v9i12.22425.</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moranne</surname><given-names>O</given-names></name><name name-style="western"><surname>Froissart</surname><given-names>M</given-names></name><name name-style="western"><surname>Rossert</surname><given-names>J</given-names></name><name name-style="western"><surname>Gauci</surname><given-names>C</given-names></name><name name-style="western"><surname>Boffa</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Haymann</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Timing of onset of CKD-related metabolic complications</article-title><source>J Am Soc Nephrol</source><year>2009</year><volume>20</volume><fpage>164</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1681/asn.2008020159</pub-id><pub-id pub-id-type="pmid">19005010</pub-id><pub-id pub-id-type="pmcid">PMC2615728</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Moranne O, Froissart M, Rossert J, Gauci C, Boffa JJ, Haymann JP, et al. Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol. 2009;20:164&#8211;71. 10.1681/asn.2008020159.<pub-id pub-id-type="pmid">19005010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.2008020159</pub-id><pub-id pub-id-type="pmcid">PMC2615728</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Seaghdha</surname><given-names>CM</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Muntner</surname><given-names>P</given-names></name><name name-style="western"><surname>Melamed</surname><given-names>ML</given-names></name><name name-style="western"><surname>Fox</surname><given-names>CS</given-names></name></person-group><article-title>Serum phosphorus predicts incident chronic kidney disease and end-stage renal disease</article-title><source>Nephrol Dial Transpl</source><year>2011</year><volume>26</volume><fpage>2885</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfq808</pub-id><pub-id pub-id-type="pmcid">PMC3175050</pub-id><pub-id pub-id-type="pmid">21292817</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">O&#8217;Seaghdha CM, Hwang SJ, Muntner P, Melamed ML, Fox CS. Serum phosphorus predicts incident chronic kidney disease and end-stage renal disease. Nephrol Dial Transpl. 2011;26:2885&#8211;90. 10.1093/ndt/gfq808.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/gfq808</pub-id><pub-id pub-id-type="pmcid">PMC3175050</pub-id><pub-id pub-id-type="pmid">21292817</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Pavan Kumar M. Clinico-pathological correlation study in chronic kidney disease patients undergoing hemodialysis. Indian J Pathol Oncol. 2023;10:141-7. 10.18231/j.ijpo.2023.030.</mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Carullo N, Sorbo D, Faga T, Pugliese S, Zicarelli MT, Costa D et al. Anemia and mineral bone disorder in kidney disease patients. The role of FGF-23 and other related factors. Int J Mol Sci. 2024;25:12838. 10.3390/ijms252312838.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms252312838</pub-id><pub-id pub-id-type="pmcid">PMC11641783</pub-id><pub-id pub-id-type="pmid">39684548</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>